Mechanism of Action: Kinase Neo Substrates

Our goal is to increase the kinase activity of the kinases we target


Neo-Substrates Have Built-In Specificity

FPO_gen_diagram.png

Meet the Core Team

Kevan Shokat, Ph.D

Co-Founder
Chairman of the Scientific Advisory Committee

Nicholas Hertz, Ph.D

Co-Founder
Chief Science Officer

Daniel de Roulet Jr.

Co-Founder
Chief Executive Officer


Mechanism of Action / Drug Profile

 

Original drug in the chemical family (kinetin) is safe at very high doses (>20mg/kg) over long periods of time in humans, but has poor PK properties Original drug in the chemical family (kinetin) is safe at very high doses (>20mg/kg) over long periods of time in humans, but has poor PK properties

 
 

Pink1/  Parkinson’s Disease

Virtually all genetic forms of Parkinson’s Disease have a mitochondrial association, and many are directly involved in the PINK1 pathway.

Learn More →

CK2/ Huntington’s Disease

Huntingtin N17-Domain Phosphorylation Is a Well-Validated Therapeutic Target Huntingtin N17-Domain Phosphorylation.

Learn More →